Market News & Trends
Calithera Biosciences Initiates Phase 1/2 Trial
Calithera Biosciences, Inc. recently announced treatment of the first patient in a Phase 1/2 open-label clinical trial of the glutaminase inhibitor telaglenastat (CB-839) in combination…
Appili Therapeutics Signs $3-Million Grant to Develop Antibiotics That Target Superbugs
Appili Therapeutics Inc. recently announced the United States Department of Defense, (DOD) Congressionally Directed Medical Research Programs, Peer Reviewed Medical Research Program (PRMRP) has completed…
Amicus Therapeutics & Brammer Bio Enter Strategic Development & Manufacturing Collaboration
Amicus Therapeutics, Inc. has entered into a strategic manufacturing collaboration with Thermo Fisher Scientific. Thermo Fisher, a best-in-class contract development and manufacturing organization (CDMO) with…
Therapeutic Solutions International Obtains Exclusive License for Patented Clinical Stage Adult Stem Cell
Therapeutics Solutions International, Inc. recently announced signing of a license agreement providing exclusive rights to a patented adult stem cell for development of therapeutics in…
Y-mAbs Announces Recruitment Status for Pivotal Trials
Y-mAbs Therapeutics, Inc. recently announced the status of patient recruitment for the company’s two pivotal Phase 2 trials, one for omburtamab for the treatment of…
Verrica Pharmaceuticals Enrolls First Patient in Phase 2 Trial
Verrica Pharmaceuticals Inc. recently announced that the first patient has been enrolled in the company’s Phase 2 ‘CARE’ clinical trial evaluating the optimal dose regimen,…
Esperion & Oberland Capital Announce $200-Million Agreement
Esperion recently announced a $200 million capped, tiered, revenue-based funding agreement on net revenues of bempedoic acid and the bempedoic acid / ezetimibe combination tablet.…
Seelos Therapeutics Announces Acquisition of Exclusive Worldwide License of Gene Therapy Program
Seelos Therapeutics, Inc. recently announced the exclusive worldwide licensing of a gene therapy program targeting the regulation of the SNCA gene, which encodes alpha-synuclein expression, …
SunGen Pharma Announces Partnership With Athenex Pharmaceutical
SunGen Pharma recently announced to launch Bivalirudin for Injection in the near future through their joint venture Peterson Athenex with Athenex Pharmaceuticals. This tentatively approved…
Wave Life Sciences Announces Initiation of Phase 2/3 Clinical Trial
Wave Life Sciences Ltd. recently announced the initiation of DYSTANCE 51, the Phase 2/3 efficacy and safety clinical trial of suvodirsen, an investigational stereopure oligonucleotide…